Crossmark

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

Crossref DOI link: https://doi.org/10.1186/s12885-018-4497-0

Published Online: 2018-05-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xie, Huyang

Zhu, Yu

Zhang, Junyu

Liu, Zheng

Fu, Hangcheng

Cao, Yifan

Li, Gaoxiang

Shen, Yijun

Dai, Bo

Xu, Jiejie https://orcid.org/0000-0001-7431-9063
Ye, Dingwei
Funding

Funding for this research was provided by:

National Key Projects for Infectious Diseases of China (2012ZX10002012-007, 2016ZX10002018-008)

National Natural Science Foundation of China (31270863, 81402082, 81472227, 81472377, 81672544)

Program for New Century Excellent Talents in University (NCET-13-0146)

Shanghai Municipal Natural Science Foundation (16ZR1406500)

Shanghai Municipal Commission of Health and Family Planning Program (20144Y0223)
License Information

Text and Data Mining valid from 2018-05-24
More Information

Article History

Received: 2 March 2017

Accepted: 9 May 2018

First Online: 24 May 2018

Ethics approval and consent to participate

: The study was approved both by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center and Zhongshan Hospital, Fudan University. Patients gave written informed consent prior to collection of any specimens.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.